Success Metrics

Clinical Success Rate
50.0%

Based on 1 completed trials

Completion Rate
50%(1/2)
Active Trials
1(20%)
Results Posted
200%(2 trials)
Terminated
1(20%)

Phase Distribution

Ph phase_3
1
20%
Ph not_applicable
1
20%
Ph phase_1
1
20%
Ph phase_2
1
20%

Phase Distribution

1

Early Stage

1

Mid Stage

1

Late Stage

Phase Distribution4 total trials
Phase 1Safety & dosage
1(25.0%)
Phase 2Efficacy & side effects
1(25.0%)
Phase 3Large-scale testing
1(25.0%)
N/ANon-phased studies
1(25.0%)

Highest Phase Reached

Phase 3

Trial Status & Enrollment

Completion Rate

50.0%

1 of 2 finished

Non-Completion Rate

50.0%

1 ended early

Currently Active

1

trials recruiting

Total Trials

5

all time

Status Distribution
Active(2)
Completed(1)
Terminated(1)
Other(1)

Detailed Status

Not yet recruiting1
unknown1
Completed1
Recruiting1
Terminated1

Development Timeline

Analytics

Development Status

Total Trials
5
Active
1
Success Rate
50.0%
Most Advanced
Phase 3

Trials by Phase

Phase 11 (25.0%)
Phase 21 (25.0%)
Phase 31 (25.0%)
N/A1 (25.0%)

Trials by Status

not_yet_recruiting120%
unknown120%
completed120%
recruiting120%
terminated120%

Recent Activity

1 active trials
Showing 5 of 5
not_yet_recruitingnot_applicable

ABL/JAK Inhibitors With Chemotherapy and Venetoclax for Ph-like ALL

NCT07454226
recruitingphase_1

A Study of SNDX-5613 in Combination With Intensive Chemotherapy in Participants With Acute Myeloid Leukemias

NCT06226571
completedphase_2

Balugrastim (Neugranin) in Breast Cancer Participants Receiving Doxorubicin/Docetaxel

NCT00837265
terminatedphase_3

Efficacy and Safety Study of PDT Using Photofrin in Unresectable Advanced Perihilar Cholangiocarcinoma (OPUS)

NCT02082522
unknown

Effect of Chemotherapy vs No Chemotherapy Pre-transplant to MDS Undergoing Allo-HSCT

NCT02850822

Clinical Trials (5)

Showing 5 of 5 trials
NCT07454226Not Applicable

ABL/JAK Inhibitors With Chemotherapy and Venetoclax for Ph-like ALL

Not Yet Recruiting
NCT06226571Phase 1

A Study of SNDX-5613 in Combination With Intensive Chemotherapy in Participants With Acute Myeloid Leukemias

Recruiting
NCT00837265Phase 2

Balugrastim (Neugranin) in Breast Cancer Participants Receiving Doxorubicin/Docetaxel

Completed
NCT02082522Phase 3

Efficacy and Safety Study of PDT Using Photofrin in Unresectable Advanced Perihilar Cholangiocarcinoma (OPUS)

Terminated
NCT02850822

Effect of Chemotherapy vs No Chemotherapy Pre-transplant to MDS Undergoing Allo-HSCT

Unknown

All 5 trials loaded

Drug Details

Intervention Type
DRUG
Total Trials
5